311 related articles for article (PubMed ID: 24238398)
1. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
Starz H; Gutschi M; Welzel J; Haas C
J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
[No Abstract] [Full Text] [Related]
2. Absent response of intracranial melanoma metastases harboring BRAF V600E sequence variation to vemurafenib.
D'Alonzo D; Glatz K
Mayo Clin Proc; 2013 Dec; 88(12):e151-2. PubMed ID: 24290130
[No Abstract] [Full Text] [Related]
3. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
Lang N; Weisser A; Enk A; Hassel JC
J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
[No Abstract] [Full Text] [Related]
4. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
5. [Treatment of metastatic melanoma with BRAF inhibitors].
Hafner C
Hautarzt; 2011 Sep; 62(9):696-8. PubMed ID: 21863388
[No Abstract] [Full Text] [Related]
6. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.
Koers K; Francken AB; Haanen JB; Woerdeman LA; van der Hage JA
J Clin Oncol; 2013 Jun; 31(16):e251-3. PubMed ID: 23569313
[No Abstract] [Full Text] [Related]
7. Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.
Nijenhuis CM; Huitema AD; Blank C; Haanen JB; van Thienen JV; Rosing H; Schellens JH; Beijnen JH
J Clin Pharmacol; 2017 Jan; 57(1):125-128. PubMed ID: 27365214
[No Abstract] [Full Text] [Related]
8. Community experience of vemurafenib for BRAF(V600) melanoma.
Hersey P
Lancet Oncol; 2014 Apr; 15(4):369-70. PubMed ID: 24582506
[No Abstract] [Full Text] [Related]
9. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
10. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment with vemurafenib in BRAF V600K-positive cerebral melanoma metastasis.
Forschner A; Niessner H; Bauer J; Bender B; Garbe C; Meier F
JAMA Dermatol; 2013 May; 149(5):642-4. PubMed ID: 23677116
[No Abstract] [Full Text] [Related]
13. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
Wagle N; Emery C; Berger MF; Davis MJ; Sawyer A; Pochanard P; Kehoe SM; Johannessen CM; Macconaill LE; Hahn WC; Meyerson M; Garraway LA
J Clin Oncol; 2011 Aug; 29(22):3085-96. PubMed ID: 21383288
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma.
Busser B; Leccia MT; Gras-Combe G; Bricault I; Templier I; Claeys A; Richard MJ; de Fraipont F; Charles J
JAMA Dermatol; 2013 Dec; 149(12):1403-6. PubMed ID: 24108467
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.
Gonzalez D; Fearfield L; Nathan P; Tanière P; Wallace A; Brown E; Harwood C; Marsden J; Whittaker S
Br J Dermatol; 2013 Apr; 168(4):700-7. PubMed ID: 23360189
[TBL] [Abstract][Full Text] [Related]
16. [BRAF mutation detection in metastatic melanoma].
Dietel M; Enk A; Lehmann A; Bauer J; Garbe C; Kellner U; Kirchner T; Jung A; Kreipe H; Merkelbach-Bruse S; Büttner R; Rüschoff J; Schlake W; Schirmacher P; Penzel R; Stadler R
Pathologe; 2012 Jul; 33(4):352-6. PubMed ID: 22692278
[No Abstract] [Full Text] [Related]
17. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
18. Strides in melanoma announced: maximizing value comes next.
Tuma RS
J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
[No Abstract] [Full Text] [Related]
19. Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?
Saint-Jean M; Quéreux G; Nguyen JM; Peuvrel L; Brocard A; Vallée A; Knol AC; Khammari A; Denis MG; Dréno B
J Invest Dermatol; 2014 May; 134(5):1468-1470. PubMed ID: 24025553
[No Abstract] [Full Text] [Related]
20. Concerns regarding BRAF testing algorithm.
Clark RR; Garioch JJ; Moncrieff MD
Br J Dermatol; 2013 Nov; 169(5):1167-8. PubMed ID: 23855527
[No Abstract] [Full Text] [Related]
[Next] [New Search]
